AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11431597
Drug: Non-programmable insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-programmable insulin pump
Trial: 8090301
Drug: Flunitrazepam 2
RxNorm normalized name: flunitrazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 2 mg (group F)
Trial: 8090301
Drug: Trazodone 50
RxNorm normalized name: traZODone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 50 mg (group T)
Trial: 31115844
Drug: Vinorelbine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine monotherapy
Trial: 24379454
Drug: Standardized music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized music therapy anger management program
Trial: 24123845
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone and Nestorone treatment after 4 weeks
Trial: 17881423
Drug: Twice-Normal Saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-Normal Saline (2NS)
Trial: 8618474
Drug: High-dose ara-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose ara-C (HIDAC)
Trial: 8618474
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction treatment (implied control)
Trial: 1579228
Drug: Intrathecal thyrotropin-releasing
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal thyrotropin-releasing hormone (TRH)
Trial: 4081627
Drug: Maprotiline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (1 mg/kg/h for 60 min, then 2 mg/kg/h until 180 min)
Trial: 18634956
Drug: Neuro-reflexotherapy intervention
RxNorm normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuro-reflexotherapy intervention (NRT) - 2 treatments, one immediately after baseline assessment and another 45 days later.
Trial: 8564883
Drug: Propranolol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (60 mg for females, 80 mg for males)
Trial: 12282175
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of RU 486 + 500 mg of sulprostone (Nalador) administered intramuscularly
Trial: 6459357
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 60 micrograms ipratropium bromide and 200 micrograms of fenoterol
Trial: 6459357
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose combinations or either drug alone
Trial: 24473704
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc supplementation for 8 weeks
Trial: 24473704
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc supplementation (Group A)
Trial: 20835926
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of stenting and external beam radiotherapy (Group II)
Trial: 21146675
Drug: Clopidogrel (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (started after surgery for 30 days) + Aspirin 81 mg daily
Trial: 21146675
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Aspirin 81 mg daily
Trial: 21146675
Drug: Clopidogrel +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel + Aspirin 81 mg daily
Trial: 17923056
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate treatment
Trial: 11915041
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose peginterferon alfa-2b (3 microg/kg for 1 week, 1.5 microg/kg for 3 weeks, and 1.0 microg/kg for 44 weeks) plus 800 mg ribavirin daily
Trial: 11915041
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose peginterferon alfa-2b (0.5 microg/kg for 48 weeks) plus 800 mg ribavirin daily
Trial: 11915041
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose peginterferon alfa-2b
Trial: 2503018
Drug: N-acetylcysteine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 200 mg three times daily with GTN 20 mg transdermal/24 h
Trial: 2503018
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with GTN 20 mg transdermal/24 h
Trial: 322243
Drug: Flurbiprofen (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (150 mg daily)
Trial: 790552
Drug: Aspirin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.6 g daily)
Trial: 27890648
Drug: Bupropion sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion sustained release (150 mg, twice a day for 12 weeks)
Trial: 19817198
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy after selective posterior rhizotomy (SPR)
Trial: 18184041
Drug: Quercetin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (1000 mg/day for 3 weeks)
Trial: 7692455
Drug: Iloprost (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (daily infusions of 6 hours)
Trial: 7692455
Drug: PGE1 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 (2 x 2 hours infusions)
Trial: 3285763
Drug: Verapamil (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (360 mg)
Trial: 3513518
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Verapamil and Propranolol
Trial: 31488098
Drug: Iron-fortified milk
RxNorm normalized name: iron succinyl milk protein complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified milk with 1.2 mg/100 mL of iron
Trial: 31488098
Drug: Iron-fortified milk
RxNorm normalized name: iron succinyl milk protein complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified milk with 0.4 mg/100 mL of iron
Trial: 31488098
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (1.2 mg and 0.4 mg of iron)
Trial: 16484822
Drug: Autologous whole
RxNorm normalized name: Autologous whole blood product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous whole blood (AWB) injections, 8 weekly intramuscular injections
Trial: 12635675
Drug: 25% aminocaproic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% aminocaproic acid (ACA) in CPM gel
Trial: 12635675
Drug: 2% carboxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% carboxy polymethylene (CPM) gel as placebo
Trial: 28506956
Drug: iCBT (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT (internet-based cognitive behavioral therapy)
Trial: 27746112
Drug: Optimum intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimum intravenous busulfan AUC of 78–101 mg×h/L
Trial: 27746112
Drug: Low historical
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low historical target of 58–86 mg×h/L
Trial: 27746112
Drug: High busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High busulfan AUC (>101 mg×h/L)
Trial: 27746112
Drug: Low AUC
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low AUC (<78 mg×h/L)
Trial: 24670970
Drug: High-dose freeze-dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose freeze-dried strawberries (HD-FDS; 50 g/d)
Trial: 24670970
Drug: Low-dose freeze-dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose freeze-dried strawberries (LD-FDS; 25 g/d)
Trial: 24670970
Drug: High-dose control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose control (HD-C)
Trial: 24670970
Drug: Low-dose control
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose control (LD-C)
Trial: 14716700
Drug: Donepezil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (up to 10 mg once daily)
Trial: 12166542
Drug: Rivastigmine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (up to 6 mg twice daily)
Trial: 10223557
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg twice daily)
Trial: 7784338
Drug: pMDI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pMDI with slow inhalation (27 l/min)
Trial: 7784338
Drug: pMDI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pMDI with fast inhalation (151 l/min)
Trial: 7784338
Drug: Nebuhaler large
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuhaler large volume spacer device (average inhaled flow 17 l/min)
Trial: 6375756
Drug: Bromhexine hydrochloride
RxNorm normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine hydrochloride 24 mg per day
Trial: 6375756
Drug: Ambroxol 90
RxNorm normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 90 mg per day
Trial: 6375756
Drug: Serratiopeptidase 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratiopeptidase 30 mg per day
Trial: 23630210
Drug: 3× HD‐AraC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3× HD‐AraC (high-dose cytarabine consolidation with three cycles of 18 g/m(2))
Trial: 23630210
Drug: MAC/MAMAC/MAC (multiagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAC/MAMAC/MAC (multiagent consolidation with two cycles of mitoxantrone 30 mg/m(2) plus cytarabine 12 g/m(2) and one cycle of amsacrine 500 mg/m(2) plus cytarabine 10 g/m(2))
Trial: 8770427
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of more than 25 tablets
Trial: 8770427
Drug: Loose preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose preparation of tablets
Trial: 8770427
Drug: Blister-pack preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blister-pack preparation of tablets
Trial: 1429086
Drug: 20 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Gy (10 x 2 Gy) to the hemithorax + CYVADIC (cyclophosphamide 500 mg/m2 d 1, vincristine 1 mg/m2 d 1 and 5, adriamycin 40 mg/m2 d 1 and dacarbazine 200 mg/m2 d 1 and 5, several cycles before and after irradiation)
Trial: 1429086
Drug: Mitoxantrone (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (14 mg/m2 q 28 d, < or = 6 cycles) followed by 70 Gy (56 x 1.25 Gy, twice a day)
Trial: 1429086
Drug: 4‐Epirubicin (110‐130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐Epirubicin (110‐130 mg/m2 q 28 d, < or = 6 cycles) followed by 35 Gy (28 x 1.25 Gy twice a day) to the hemithorax + 36 Gy (9 x 4 Gy every 2 days) to the tumor
Trial: 1429086
Drug: Etoposide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (150 mg/m2 1, 3, 5 q 28 d) followed by 38.5 Gy (11 x 3.5 Gy) to the hemithorax
Trial: 1429086
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment programs
Trial: 3882141
Drug: Cyclosporine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (12.5 mg/kg/d orally or 3 mg/kg/d i.v.)
Trial: 31204776
Drug: CBT-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-based occupational therapy with sensor monitoring
Trial: 25932956
Drug: Galactose (GAL)
RxNorm normalized name: Galactose
DrugBank: Galactose (DB11735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactose (GAL) drink (45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Trial: 25932956
Drug: Glucose (GLU)
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (GLU) drink (45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Trial: 25932956
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) drink (artificially sweetened, 45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Trial: 25932956
Drug: Galactose (GAL)
RxNorm normalized name: Galactose
DrugBank: Galactose (DB11735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactose (GAL) drink (45 g of CHO)
Trial: 17643057
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2 x 600 mg orally for 6 weeks
Trial: 12394531
Drug: Piracetam (7.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (7.2 g daily for the first 2 weeks during ECT, followed by 4.8 g thereafter)
Trial: 10687162
Drug: Diosmectite (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmectite (3 g/day for children under 3 years and 6 g/day for children over 3 years)
Trial: 10687162
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (ORS) only
Trial: 2205129
Drug: Fasting for
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting for 2 hours with 2 mL/kg of water
Trial: 25377657
Drug: Daily low-emission
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily low-emission UV treatment and mometasone ointment 0.1%
Trial: 25377657
Drug: Mometasone ointment
RxNorm normalized name: mometasone Topical Ointment
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone ointment 0.1% alone
Trial: 7838889
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BMS-181168
Trial: 7838889
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BMS-181168
Trial: 7838889
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg BMS-181168
Trial: 3283620
Drug: Intensive maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive maintenance treatment (rotating combination of HD‐Ara C, mAMSA, 5‐AZA)
Trial: 3283620
Drug: Repeated induction
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated induction type chemotherapy (DNM, VCR, Ara C)
Trial: 3283620
Drug: Conventional maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional maintenance treatment (from a preceding randomized study)
Trial: 30816632
Drug: Implant
RxNorm normalized name: IMPLANT (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant
Trial: 25650633
Drug: Ultrasound-guided supraclavicular
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided supraclavicular blockade with 30 mL of 0.5% ropivacaine
Trial: 25650633
Drug: Ultrasound-guided infraclavicular
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultrasound-guided infraclavicular blockade with 30 mL of 0.5% ropivacaine
Trial: 23974885
Drug: Ocular lubricants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular lubricants (OLs) 4 times a day with Lacri-Lube ointment at night for 3 months
Trial: 18775918
Drug: Adjunctive manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive manual thrombectomy
Trial: 16416358
Drug: Amitriptyline-gabapentin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline-gabapentin combination
Trial: 10700783
Drug: Rapacuronium 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 2.5 mg kg‐1
Trial: 10700783
Drug: Succinylcholine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.5 mg kg‐1
Trial: 25786811
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml ropivacaine 0.5%
Trial: 25786811
Drug: 125 ml
RxNorm normalized name: 125 ML argatroban 1 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 ml ropivacaine 0.2%
Trial: 25786811
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml 0.9% saline (placebo)
Trial: 19546825
Drug: Bazedoxifene 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 10, 20, or 40 mg
Trial: 17692722
Drug: Valdecoxib 10
RxNorm normalized name: valdecoxib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 10 mg QD
Trial: 16678642
Drug: Valdecoxib 20
RxNorm normalized name: valdecoxib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 20 mg QD
Trial: 16678642
Drug: Valdecoxib 40
RxNorm normalized name: valdecoxib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 40 mg QD
Trial: 9250559
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg administered orally once/day for 12 days
Trial: 9250559
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once/day for 12 days
Trial: 8318063
Drug: Lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40 mg once daily)
Trial: 29720027
Drug: Testosterone enantholactam
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone enantholactam acid ester (250 mg, intramuscular injection every 2 weeks for 6 months)
Trial: 29720027
Drug: Placebo (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscular injection every 2 weeks for 6 months)
Trial: 20127900
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion plus N-acetylcysteine (NAC)
Trial: 20127900
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (SB) infusion
Trial: 3117914
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg) pre-operatively
Trial: 3117914
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate (30 mg) pre-operatively
Trial: 3117914
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ibuprofen/codeine (400 mg/30 mg) pre-operatively
Trial: 3117914
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ibuprofen/codeine (400 mg/30 mg) post-operatively
Trial: 3117914
Drug: Diflunisal (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (250 mg) post-operatively
Trial: 27300113
Drug: Stretching (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching (10 minutes daily before bedtime for 3 weeks)
Trial: 18545070
Drug: High-dose simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose simvastatin (80 mg/day)
Trial: 18545070
Drug: Low-dose simvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose simvastatin (20 mg/day)
Trial: 11760378
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) therapy at a dose of 20 ppm
Trial: 9406362
Drug: Teicoplanin administered
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin administered at the time of insertion of central venous catheters
Trial: 8123209
Drug: Nimodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (30 and 60 mg, PO)
Trial: 8123209
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg, PO)
Trial: 8123209
Drug: Nimodipine, Verapamil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine, Verapamil, Alcohol (in combination)
Trial: 14520164
Drug: Donepezil (DPZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (DPZ), 5 to 10 mg for 30 days
Trial: 31791389
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy-oriented psychoeducation and self-managed exposure exercises delivered in four manual-based appointments with a general practitioner, along with case management by a trained health care assistant and eHealth support.
Trial: 31791389
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy, case management, eHealth support (combined intervention).
Trial: 15536018
Drug: Lisinopril therapy
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril therapy for 2 months